| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Can we improve on ibrutinib in mantle cell lymphoma?
|
Rule, Simon
|
|
2018
|
5 |
3 |
p. e98-e99
|
artikel
|
| 2 |
CAR T-cell design: a long road ahead
|
The Lancet Haematology,
|
|
2018
|
5 |
3 |
p. e95
|
artikel
|
| 3 |
Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited?
|
Gordon, Leo I
|
|
2018
|
5 |
3 |
p. e96-e97
|
artikel
|
| 4 |
Good news for patients with myelodysplastic syndromes and thrombocytopenia
|
Mittelman, Moshe
|
|
2018
|
5 |
3 |
p. e100-e101
|
artikel
|
| 5 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
|
Jerkeman, Mats
|
|
2018
|
5 |
3 |
p. e109-e116
|
artikel
|
| 6 |
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
|
Kantarjian, Hagop M
|
|
2018
|
5 |
3 |
p. e117-e126
|
artikel
|
| 7 |
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study
|
Barr, Paul M
|
|
2018
|
5 |
3 |
p. e102-e108
|
artikel
|
Tijdschrift beschrijving